FTSE 100 today: Index edges higher; Centrica gains on Sizewell C stake
Kamada Ltd (NASDAQ:KMDA)., a pharmaceutical company, has announced that it will release its financial results for the first quarter of 2025 on May 14, 2025. The announcement was made in a recent filing with the U.S. Securities and Exchange Commission (SEC).
The company, which is known for its work in the pharmaceutical preparations sector, is headquartered in Rehovot, Israel. Kamada Ltd. is incorporated under the laws of the State of Israel and has its fiscal year ending on December 31.
The SEC filing, a Form 6-K, serves as a report of foreign private issuers pursuant to rules 13a-16 and 15d-16 of the Securities Exchange Act of 1934. In this filing, Kamada Ltd. indicates that it files annual reports under Form 20-F. The Form 6-K is also incorporated by reference into the registrant’s Form S-8 Registration Statements, which are a part of the U.S. securities law requirements for companies offering stock incentives to their employees.
The document was signed on behalf of Kamada Ltd. by Nir Livneh, Vice President General Counsel and Corporate Secretary, as required by the Securities Exchange Act of 1934. This formal announcement sets the stage for investors and analysts to receive updated financial information about the company’s performance in the upcoming weeks.
This news is based on a press release statement and provides investors with the date to expect comprehensive financial data from Kamada Ltd. The financial results will provide insights into the company’s earnings, profitability, and operational performance for the first quarter of the year.
Investors and stakeholders in the pharmaceutical industry will be looking forward to Kamada Ltd.’s financial results to gauge the company’s health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.